drugset
drugset / Trial / NCT04601688

Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

NCT04601688 ↗

Unknown 100 enrolled He Eye Hospital
Non-randomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Bevacizumab or combination of Bevacizumab And Dexamethasone under pro re nata treatment regimen for Branch Retinal Vein Occlusion (BRVO) patients.

Timeline

Start
2020-10-31
Primary completion
2021-03-02
Completion
2021-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — Other
Subject Dexamethasone Small molecule — Intravitreal

Indications

retinal vein occlusion